Royal Bank of Canada
CHRS icon

Royal Bank of Canada’s Coherus Oncology CHRS Stock Holding History

Royal Bank of Canada’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5K Sell
3,080
-1,995
-39% -$3.54K ﹤0.01% 6404
2025
Q4 		$7K Sell
5,075
-330,424
-98% -$481K ﹤0.01% 6573
2025
Q3 		$551K Sell
335,499
-4,510
-1% -$5.02K ﹤0.01% 4415
2025
Q2 		$248K Buy
340,009
+334,271
+5,826% +$289K ﹤0.01% 4994
2025
Q1 		$4K Sell
5,738
-5,331
-48% -$6.13K ﹤0.01% 6396
2024
Q4 		$15K Sell
11,069
-2,346
-17% -$2.63K ﹤0.01% 6217
2024
Q3 		$14K Buy
13,415
+3,062
+30% +$4.2K ﹤0.01% 6222
2024
Q2 		$18K Buy
10,353
+5,713
+123% +$11.5K ﹤0.01% 6109
2024
Q1 		$11K Sell
4,640
-27,292
-85% -$67.2K ﹤0.01% 6153
2023
Q4 		$107K Sell
31,932
-5,056
-14% -$13.5K ﹤0.01% 5579
2023
Q3 		$139K Buy
36,988
+9,659
+35% +$44.6K ﹤0.01% 5121
2023
Q2 		$117K Buy
27,329
+677
+3% +$4K ﹤0.01% 5203
2023
Q1 		$182K Sell
26,652
-4,651
-15% -$36.1K ﹤0.01% 4708
2022
Q4 		$248K Buy
31,303
+1,714
+6% +$13.2K ﹤0.01% 4687
2022
Q3 		$285K Sell
29,589
-10,137
-26% -$103K ﹤0.01% 4473
2022
Q2 		$287K Buy
39,726
+13,784
+53% +$120K ﹤0.01% 4502
2022
Q1 		$336K Sell
25,942
-7,607
-23% -$96.7K ﹤0.01% 4624
2021
Q4 		$535K Buy
33,549
+8,127
+32% +$142K ﹤0.01% 4385
2021
Q3 		$408K Sell
25,422
-11,800
-32% -$173K ﹤0.01% 4521
2021
Q2 		$516K Sell
37,222
-3,354
-8% -$47.5K ﹤0.01% 4242
2021
Q1 		$593K Sell
40,576
-8,435
-17% -$143K ﹤0.01% 4033
2020
Q4 		$851K Buy
49,011
+6,390
+15% +$114K ﹤0.01% 3642
2020
Q3 		$781K Buy
42,621
+3,398
+9% +$63.2K ﹤0.01% 3469
2020
Q2 		$701K Buy
39,223
+3,153
+9% +$53.4K ﹤0.01% 3483
2020
Q1 		$585K Sell
36,070
-10,608
-23% -$196K ﹤0.01% 3471
2019
Q4 		$840K Buy
46,678
+1,099
+2% +$20.3K ﹤0.01% 3586
2019
Q3 		$924K Buy
45,579
+18,870
+71% +$377K ﹤0.01% 3403
2019
Q2 		$590K Sell
26,709
-886
-3% -$15.4K ﹤0.01% 3741
2019
Q1 		$377K Sell
27,595
-68,403
-71% -$913K ﹤0.01% 3939
2018
Q4 		$869K Buy
95,998
+67,079
+232% +$776K ﹤0.01% 3277
2018
Q3 		$477K Sell
28,919
-3,991
-12% -$70.7K ﹤0.01% 3930
2018
Q2 		$461K Buy
32,910
+384
+1% +$5.5K ﹤0.01% 3845
2018
Q1 		$360K Buy
32,526
+6,754
+26% +$73.9K ﹤0.01% 3933
2017
Q4 		$227K Buy
25,772
+18,650
+262% +$200K ﹤0.01% 4341
2017
Q3 		$95K Buy
7,122
+3,724
+110% +$49.3K ﹤0.01% 5049
2017
Q2 		$48K Buy
3,398
+2,001
+143% +$38.5K ﹤0.01% 5136
2017
Q1 		$29K Sell
1,397
-582
-29% -$14.3K ﹤0.01% 5423
2016
Q4 		$56K Sell
1,979
-15,621
-89% -$437K ﹤0.01% 5198
2016
Q3 		$471K Buy
17,600
+17,000
+2,833% +$464K ﹤0.01% 3766
2016
Q2 		$10K Sell
600
-15,600
-96% -$293K ﹤0.01% 5739
2016
Q1 		$344K Buy
16,200
+16,185
+107,900% +$265K ﹤0.01% 3948
2015
Q4 		$0 Sell
15
-1,021
-99% -$26.3K ﹤0.01% 6648
2015
Q3 		$21K Sell
1,036
-24,794
-96% -$754K ﹤0.01% 5550
2015
Q2 		$746K Buy
+25,830
New +$653K ﹤0.01% 3184
2015
Q1 		– Sell
-33
Closed -$1K – 6153
2014
Q4 		$1K Buy
+33
New +$466 ﹤0.01% 6031

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Royal Bank of Canada's CHRS Position: Q1 2026 in Review

Royal Bank of Canada reduced its Coherus Oncology (CHRS) stake by 39% in Q1 2026, selling an estimated $3.54K and leaving 3,080 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #6404.

Royal Bank of Canada first reported a position in CHRS in Q4 2014 and has held it in 45 quarters since. The position peaked at $924K in Q3 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Royal Bank of Canada held 3,080 shares of Coherus Oncology worth $5K as of Q1 2026.
  • Royal Bank of Canada sold 1,995 Coherus Oncology shares in Q1 2026, an estimated $3.54K.
  • Coherus Oncology made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6404 holding.
  • Royal Bank of Canada first reported a position in Coherus Oncology in Q4 2014 and has held it in 45 quarters since.
  • Royal Bank of Canada's Coherus Oncology position peaked at $924K in Q3 2019.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.